Looking Ahead: How private equity and other investors, business leaders, developers, and municipalities can benefit from Opportunity Zones in the Commonwealth of Massachusetts
07 February 2019
Join us for a discussion of Opportunity Zones, including such topics as federal tax incentives, location of Qualified Opportunity Zones within the Commonwealth, and the ability to combine federal Opportunity Zone benefits with state and municipal incentives.
Confirmed speakers include:
- Governor Charlie Baker, Commonwealth of Massachusetts
- Mike Kennealy, Secretary, Executive Office of Housing and Economic Development, Commonwealth of Massachusetts
- Mayor Martin Walsh, City of Boston
- Lauren Liss, President and CEO, MassDevelopment
- Dan Kowalski, Counsel to the Secretary, United States Department of Treasury
- Gary Hecimovich, Partner, Deloitte Tax LLP
- Daniel Barile, CFA, Partner, Portfolio Manager, Senior Investment Analyst, Skybridge Capital
- Paul Farrell, Senior Adviser, New Mountain Capital
This is a private event by invitation only. For more information, please contact Diana Lauritson at [email protected].
People
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…